• About us
• Contact

Advertisement

Organisation › Details

BioNTech RNA Pharmaceuticals GmbH

BioNTech RNA Pharmaceuticals GmbH is a fully-owned subsidiary company within the BioNTech AG Group. The company is a technology leader in the rapidly growing field of synthetic messenger RNA (mRNA) therapeutics. Its system is based on the precise delivery of potent, long-lived synthetic mRNA into target cells. Following delivery of the mRNA, patients’ cells produce the mRNA-encoded protein, which is the pharmacologically active product. BioNTech is currently performing clinical trials to develop the concept of tailored multivalent Mutanome Vaccines. *

 

	Start	2014-03-06 renamed
	Group	BioNTech (Group)
	Predecessor	Ribological GmbH
	Industry	BIOTECH
	Industry 2	RNAi drug (RNAi therapeutic)
	Person	Pötting, Sierk (BioNTech 202107– COO joined 201409 as CFO before Sandoz Inc/Novartis + McKinsey)
	Person 2	Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
	Region	Mainz
	Country	Germany
	Street	12 An der Goldgrube
	City	55131 Mainz
		Address record changed: 2020-12-02
Basic data	Employees	B: 11 to 50 (2011-12-25)
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for BioNTech (Group)

• [1] Ryvu Therapeutics S.A.. (2/25/25). "Press Release: Ryvu Therapeutics Announces Strategic Reorganization to Extend the Cash Runway for the Development of RVU120 and the Preclinical Pipeline". Krakow....
• [2] BioNTech SE. (11/13/24). "Press Release: BioNTech to Acquire Biotheus to Boost Oncology Strategy". Mainz....
• [3] Tempus AI, Inc.. (9/4/24). "Press Release: Tempus Announces Real World Data Collaboration with BioNTech". Chicago....
• [4] BioNTech SE. (8/22/24). "Press Release: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine". New York, NY & Mainz....
• [5] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
• [6] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
• [7] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....
• [8] Triastek, Inc.. (7/23/24). "Press Release: Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics". Nanjing....
• [9] Haya Therapeutics SA. (7/1/24). "Press Release: Haya Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award". Lausanne & San Diego, CA....
• [10] BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.